EC Number   |
Protein Variants |
Reference  |
|---|
   3.4.22.B50 | C1651A |
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues |
-, 670084 |
| 3.4.22.B50 | C1732A |
encodes a substitution of a cysteine residue, predicted to be critical for zinc binding |
-, 670084 |
| 3.4.22.B50 | D1826A |
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues |
-, 670084 |
| 3.4.22.B50 | C1651A |
Plpro active-site mutant |
-, 670085 |
| 3.4.22.B50 | C106A |
inactive |
718275 |
| 3.4.22.B50 | C112S |
site-directed mutagenesis, the C112S mutant is monomeric, ubiquitin binding crystal structure analysis, overview |
731069 |
| 3.4.22.B50 | D165A |
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme |
731069 |
| 3.4.22.B50 | E168A |
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme |
731069 |
| 3.4.22.B50 | E168D |
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme |
731069 |
| 3.4.22.B50 | E168R |
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme |
731069 |
